Published in Cancer Weekly, February 1st, 2005
Immunologists in England "showed previously that tumor-derived supernatant (TSN)" from AML myeloblasts "inhibits peripheral blood T-cell activation and proliferation, rendering the T cells functionally incompetent."
In their subsequent study, D. Milojkovic and coauthors at the Rayne Institute in London found that "the AML TSN also significantly delays apoptosis of both resting and stimulated T cells, as judged by reduction in annexin V/propidium iodide staining."
"In addition, we show that this is not unique to T cells and that AML TSN...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.